Pulmonx (NASDAQ: LUNG) has reaffirmed its full-year 2026 sales guidance, maintaining the range of $90.000 million to $92.000 million. The updated outlook remains unchanged from previous statements and sits in line with the consensus analyst estimate of $90.832 million. This affirmation provides clarity to investors regarding the company’s revenue trajectory for the fiscal year, suggesting that management sees no material deviation from prior expectations despite broader market dynamics.

The guidance reaffirmation was disclosed in a recent filing, confirming that the company’s operational performance continues to track within the expected parameters. By keeping the guidance intact, Pulmonx signals confidence in its ability to deliver on its financial targets. The midpoint of the guidance range is $91.000 million, which slightly exceeds the street estimate, offering a modest buffer against potential shortfalls.

Financial Outlook Details

The following table outlines the key components of Pulmonx’s FY2026 sales guidance:

What the Numbers Show

The alignment between Pulmonx’s guidance and the analyst estimate suggests a high degree of market consensus on the company’s near-term revenue potential. With the estimate falling within the lower half of the guided range, there is room for upside surprise if execution remains strong. However, the narrowness of the range ($2.000 million spread) indicates limited volatility in expected demand or pricing power for Pulmonx’s products in FY2026.

Pulmonx Corporation (NASDAQ: LUNG) will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. The session is scheduled to begin at 1:00 PM PT / 4:00 PM ET. Investors can access a live and archived webcast of the presentation through the "Investors" section of the Pulmonx website.

Event Details

The conference provides an opportunity for the company to engage with investors regarding its business strategy and market position. The fireside chat format allows for direct interaction between company executives and financial analysts.

About Pulmonx Corporation

Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company’s portfolio includes the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports. These solutions are designed to assess and treat patients with severe emphysema/COPD who remain profoundly symptomatic despite medical management.

Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr Endobronchial Valve following its designation as a "breakthrough device." The Zephyr Valve is commercially available in more than 25 countries and is included in global treatment guidelines. It is widely considered a standard of care treatment option for improving breathing, activity, and quality of life in patients with severe emphysema.